Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.31 million.

For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.

Earnings